ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02954874
Recruitment Status : Recruiting
First Posted : November 4, 2016
Last Update Posted : July 20, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 31, 2026
  Study Completion Date : No date given